MetaCap

MaxCyte Inc. (MXCT)

NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

1.37+0.09 (+7.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MXCT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$141.45M
EPS (TTM)
-$0.26
52-week range
0.643 – 1.80
Day range
1.27 – 1.42
Volume / Avg
1.11M / 1.04M
Beta
—

52-week range

$0.643$1.80

MXCT stock today

Shares of MaxCyte (MXCT) finished higher on Nov 20 at $1.37, a gain of 7.03% or $0.09 per share, versus the S&P 500's 3.70% decline. At this level, MXCT sits in the middle of its 52-week range of $0.643 to $1.80: 23.9% below the high, set on Nov 28, 2025 and 113.1% above the low. MXCT is down 11.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 18.0%.

MaxCyte has posted a net loss over the last twelve months (EPS of -$0.26), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About MaxCyte

Company profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.

Industry
Biotechnology: Commercial Physical & Biological Resarch
CEO
Mr. Maher Masoud
Headquarters
Rockville, MD
Employees
91
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, MaxCyte generated $33.0 million in revenue, down 14.5% from fiscal 2024, its first annual decline since 2024. MaxCyte reported a net loss of $44.6 million, compared with a loss of $41.1 million a year earlier. Gross margin was 81.2% (down from 81.6%) and operating margin -157.1%.

MaxCyte annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$33.03M$38.63M$41.29M$44.26M$33.89M
Growth-14.50%-6.44%-6.72%+30.59%+29.52%
Net income$-44.63M$-41.05M$-37.92M$-23.57M$-19.08M
EPS (diluted)$-0.42$-0.39$-0.37$-0.23$-0.21

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$4.11+200.00%

  • Strong buy 0
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.43High $5.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.05 vs $-0.08
Surprise
+37.50%

MXCT news

All MXCT news

MaxCyte peers

Health Care sector
MXCT peer companies
CompanyPrice% ChgMarket capCompare
ONMDOneMedNet Corp Class A4.70+4.21%$29.15Mvs MXCT
BIAFbioAffinity Technologies Inc.1.65-10.81%$3.00Mvs MXCT
ISPCiSpecimen Inc.0.4563-13.58%$2.64Mvs MXCT
NRCNRC Health25.16+0.68%$533.93Mvs MXCT
OABIOmniAb Inc.4.66-7.36%$679.71Mvs MXCT
ABSIAbsci Corporation7.51-7.97%$1.30Bvs MXCT
ICLRICON plc186.71-1.92%$13.99Bvs MXCT
CRLCharles River Laboratories International Inc.314.32-4.15%$15.06Bvs MXCT

Indexes, lists and sector

MaxCyte stock FAQ

What is MaxCyte's stock price today?

MXCT last traded at $1.37 as of Nov 20, 4:00 PM EST, up 7.03% on the day. Prices are delayed at least 15 minutes.

Who is MaxCyte's CEO?

Mr. Maher Masoud is the chief executive officer of MaxCyte Inc., which has about 91 employees.

What is the MXCT 52-week high?

The 52-week high for MXCT is $1.80 and the 52-week low is $0.643. The stock is currently 23.9% below its high.

Compare MXCT